These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 35781796)

  • 1. Clinical grade ACE2 as a universal agent to block SARS-CoV-2 variants.
    Monteil V; Eaton B; Postnikova E; Murphy M; Braunsfeld B; Crozier I; Kricek F; Niederhöfer J; Schwarzböck A; Breid H; Devignot S; Klingström J; Thålin C; Kellner MJ; Christ W; Havervall S; Mereiter S; Knapp S; Sanchez Jimenez A; Bugajska-Schretter A; Dohnal A; Ruf C; Gugenberger R; Hagelkruys A; Montserrat N; Kozieradzki I; Hasan Ali O; Stadlmann J; Holbrook MR; Schmaljohn C; Oostenbrink C; Shoemaker RH; Mirazimi A; Wirnsberger G; Penninger JM
    EMBO Mol Med; 2022 Aug; 14(8):e15230. PubMed ID: 35781796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical grade ACE2 as a universal agent to block SARS-CoV-2 variants.
    Wirnsberger G; Monteil V; Eaton B; Postnikova E; Murphy M; Braunsfeld B; Crozier I; Kricek F; Niederhöfer J; Schwarzböck A; Breid H; Jimenez AS; Bugajska-Schretter A; Dohnal A; Ruf C; Gugenberger R; Hagelkruys A; Montserrat N; Holbrook MR; Oostenbrink C; Shoemaker RH; Mirazimi A; Penninger JM
    bioRxiv; 2021 Sep; ():. PubMed ID: 34545368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High activity of an affinity-matured ACE2 decoy against Omicron SARS-CoV-2 and pre-emergent coronaviruses.
    Sims JJ; Lian S; Meggersee RL; Kasimsetty A; Wilson JM
    PLoS One; 2022; 17(8):e0271359. PubMed ID: 36006993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An engineered ACE2 decoy neutralizes the SARS-CoV-2 Omicron variant and confers protection against infection in vivo.
    Ikemura N; Taminishi S; Inaba T; Arimori T; Motooka D; Katoh K; Kirita Y; Higuchi Y; Li S; Suzuki T; Itoh Y; Ozaki Y; Nakamura S; Matoba S; Standley DM; Okamoto T; Takagi J; Hoshino A
    Sci Transl Med; 2022 Jun; 14(650):eabn7737. PubMed ID: 35471044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rational design of AAVrh10-vectored ACE2 functional domain to broadly block the cell entry of SARS-CoV-2 variants.
    Li M; Chen J; Liu Y; Zhao J; Li Y; Hu Y; Chen YQ; Sun L; Shu Y; Feng F; Sun C
    Antiviral Res; 2022 Sep; 205():105383. PubMed ID: 35917969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Host chitinase 3-like-1 is a universal therapeutic target for SARS-CoV-2 viral variants in COVID-19.
    Kamle S; Ma B; Lee CM; Schor G; Zhou Y; Lee CG; Elias JA
    Elife; 2022 Jun; 11():. PubMed ID: 35735790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Potential ACE2-Derived Peptide Mimetics in SARS-CoV-2 Omicron Variant Therapeutics using Computational Approaches.
    Paul S; Nadendla S; Sobhia ME
    J Phys Chem Lett; 2022 Aug; 13(32):7420-7428. PubMed ID: 35929665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An ACE2 decoy can be administered by inhalation and potently targets omicron variants of SARS-CoV-2.
    Zhang L; Narayanan KK; Cooper L; Chan KK; Skeeters SS; Devlin CA; Aguhob A; Shirley K; Rong L; Rehman J; Malik AB; Procko E
    EMBO Mol Med; 2022 Nov; 14(11):e16109. PubMed ID: 36094679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computational modeling of the effect of five mutations on the structure of the ACE2 receptor and their correlation with infectivity and virulence of some emerged variants of SARS-CoV-2 suggests mechanisms of binding affinity dysregulation.
    Rodriguez JA; Gonzalez J; Arboleda-Bustos CE; Mendoza N; Martinez C; Pinzon A
    Chem Biol Interact; 2022 Dec; 368():110244. PubMed ID: 36336003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants.
    Ferrari M; Mekkaoui L; Ilca FT; Akbar Z; Bughda R; Lamb K; Ward K; Parekh F; Karattil R; Allen C; Wu P; Baldan V; Mattiuzzo G; Bentley EM; Takeuchi Y; Sillibourne J; Datta P; Kinna A; Pule M; Onuoha SC
    J Virol; 2021 Sep; 95(19):e0068521. PubMed ID: 34287040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Receptor binding domain of SARS-CoV-2 from Wuhan strain to Omicron B.1.1.529 attributes increased affinity to variable structures of human ACE2.
    Patil S; Alzahrani KJ; Banjer HJ; Halawani IF; Alzahrani H; Altayar MA; Albogami S; Angeles RF; Hassan AAA; Bhandi S; Raj AT
    J Infect Public Health; 2022 Jul; 15(7):781-787. PubMed ID: 35738053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced binding and inhibition of SARS-CoV-2 by a plant-derived ACE2 protein containing a fused mu tailpiece.
    Lim S; Kwon HJ; Jeong DG; Nie H; Lee S; Ko SR; Lee KS; Ryu YB; Mason HS; Kim HS; Shin AY; Kwon SY
    Biotechnol J; 2024 Jan; 19(1):e2300319. PubMed ID: 37853601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Spike Mutations in SARS-CoV-2 Variants of Concern on Human or Animal ACE2-Mediated Virus Entry and Neutralization.
    Kim Y; Gaudreault NN; Meekins DA; Perera KD; Bold D; Trujillo JD; Morozov I; McDowell CD; Chang KO; Richt JA
    Microbiol Spectr; 2022 Jun; 10(3):e0178921. PubMed ID: 35638818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
    Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
    mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epistasis at the SARS-CoV-2 Receptor-Binding Domain Interface and the Propitiously Boring Implications for Vaccine Escape.
    Rochman ND; Faure G; Wolf YI; Freddolino PL; Zhang F; Koonin EV
    mBio; 2022 Apr; 13(2):e0013522. PubMed ID: 35289643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble wild-type ACE2 molecules inhibit newer SARS-CoV-2 variants and are a potential antiviral strategy to mitigate disease severity in COVID-19.
    Ameratunga R; Mears E; Leung E; Snell R; Woon ST; Kelton W; Medlicott N; Jordan A; Abbott W; Steele R; Rolleston W; Longhurst H; Lehnert K
    Clin Exp Immunol; 2023 Dec; 214(3):289-295. PubMed ID: 37565297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of an aerosol intervention for COVID-19 disease: Tolerability of soluble ACE2 (APN01) administered via nebulizer.
    Shoemaker RH; Panettieri RA; Libutti SK; Hochster HS; Watts NR; Wingfield PT; Starkl P; Pimenov L; Gawish R; Hladik A; Knapp S; Boring D; White JM; Lawrence Q; Boone J; Marshall JD; Matthews RL; Cholewa BD; Richig JW; Chen BT; McCormick DL; Gugensberger R; Höller S; Penninger JM; Wirnsberger G
    PLoS One; 2022; 17(7):e0271066. PubMed ID: 35816490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A computationally designed ACE2 decoy has broad efficacy against SARS-CoV-2 omicron variants and related viruses in vitro and in vivo.
    Havranek B; Lindsey GW; Higuchi Y; Itoh Y; Suzuki T; Okamoto T; Hoshino A; Procko E; Islam SM
    Commun Biol; 2023 May; 6(1):513. PubMed ID: 37173421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxalic acid blocked the binding of spike protein from SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) variants to human angiotensin-converting enzymes 2.
    Wang M; Yan H; Chen L; Wang Y; Li L; Zhang H; Miao L
    PLoS One; 2023; 18(5):e0285722. PubMed ID: 37200310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy.
    Datta PK; Liu F; Fischer T; Rappaport J; Qin X
    Theranostics; 2020; 10(16):7448-7464. PubMed ID: 32642005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.